Review

anti foxp3 (Cell Signaling Technology Inc)

Cell Signaling Technology Inc is a verified supplier

Cell Signaling Technology Inc manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Cell Signaling Technology Inc anti foxp3
Anti Foxp3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti foxp3/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews

anti foxp3 - by Bioz Stars, 2026-05

86/100 stars

Images

Image Search Results

Treg cell depletion unleashes IFNγ-producing γδ T cell responses. (A) Schematic representation of the experimental approach. 1 × 10 6 of E0771 breast cancer cells were inoculated subcutaneously in the mammary fat pad of Foxp3-DTR mice. DTx in PBS was administered intraperitoneally on days 7, 9, 11 (50 μg/kg), and 14 (25 μg/kg) after tumor inoculation. (B) Percentages of Treg cells in tumors at day 15 after tumor inoculation ( n = 12 mice per group), represented as means ± SEM and analyzed by Mann–Whitney U test. (C) Tumor growth of PBS- or DTx-treated mice ( n = 14 mice per group). Means ± SEM, repeated measures two-way ANOVA with Sidak’s multiple comparisons test. (D) Fold change of numbers of γδ T cells per milligram of tumor ( n = 22 control and 23 DTx mice), normalized over controls, represented as means ± SEM and analyzed by the Mann–Whitney U test. Data in B–D represent a pool of three independent experiments. (E) Unsupervised hierarchical clustering of tumor-infiltrating γδ T cells from PBS (pool of n = 3 mice) or DTx-treated mice (pool of n = 3 mice), based on spectral flow cytometry data. (F) Distribution of clusters across the individual mice ( n = 6). (G) Protein expression levels of different markers across clusters. Data in E–G represent one representative experiment out of >3 independent experiments. (H) Representative density plots (gated on γδ T cells) and quantification of IFNγ + γδ T cells in tumors ( n = 22 control and 23 DTx mice). Fold change of percentage, numbers per milligram, and mean fluorescence intensity (MFI) over controls are represented. (I) Fold change of percentage of IL-17A + γδ T cells and numbers per milligram in tumors ( n = 22 Control and 23 DTx mice). (J) γδ T cell polarization measured by the ratio of percentages of IFNγ + versus IL-17A + γδ T cells (γδIFN/γδ17) ( n = 18 control and 19 DTx mice). Data in H–J are a pool of three different experiments. (K) Representative density plots (gated on IFNγ + γδ T cells) and quantification of proliferation of tumor IFNγ + γδ T cells, measured by Ki-67 ( n = 5 control 7 DTx mice) and BrdU ( n = 7 mice per group) staining. One representative out of two independent experiments. (L) Fold change of percentages of IFNγ + γδ T cells in the tumor dLNs spleen of control and DTx-treated mice ( n = 22 control and 23 DTx mice). (M) Fold change of percentages of Vγ subsets (within γδ T cells) in the tumors ( n = 22 control and 23 DTx mice). Data in L and M are a pool of three different experiments. (N) Fold change of percentages of granzyme B + cells within γδ T cells in tumors ( n = 10 control and 12 DTx mice), one representative out of three independent experiments. Data in H-N represented as means ± SEM and analyzed by unpaired t test for normal distributions or Mann–Whitney U test for non-normal distributions. (O) Quantification of tumor cell death of E0771 cells over a 24-h killing assay in the presence of γδ T cells, Treg cells, or both, measured by percentage of annexin V + cells ( n = 3–4 replicates). Data are represented as means ± SEM and analyzed by one-way ANOVA with Tukey’s post hoc test. One representative out of two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, and****P < 0.001.

Journal: The Journal of Experimental Medicine

Article Title: Regulatory T cells sabotage anti-tumor γδ T cells by creating IL-2–deficient environments

doi: 10.1084/jem.20252133

Figure Lengend Snippet: Treg cell depletion unleashes IFNγ-producing γδ T cell responses. (A) Schematic representation of the experimental approach. 1 × 10 6 of E0771 breast cancer cells were inoculated subcutaneously in the mammary fat pad of Foxp3-DTR mice. DTx in PBS was administered intraperitoneally on days 7, 9, 11 (50 μg/kg), and 14 (25 μg/kg) after tumor inoculation. (B) Percentages of Treg cells in tumors at day 15 after tumor inoculation ( n = 12 mice per group), represented as means ± SEM and analyzed by Mann–Whitney U test. (C) Tumor growth of PBS- or DTx-treated mice ( n = 14 mice per group). Means ± SEM, repeated measures two-way ANOVA with Sidak’s multiple comparisons test. (D) Fold change of numbers of γδ T cells per milligram of tumor ( n = 22 control and 23 DTx mice), normalized over controls, represented as means ± SEM and analyzed by the Mann–Whitney U test. Data in B–D represent a pool of three independent experiments. (E) Unsupervised hierarchical clustering of tumor-infiltrating γδ T cells from PBS (pool of n = 3 mice) or DTx-treated mice (pool of n = 3 mice), based on spectral flow cytometry data. (F) Distribution of clusters across the individual mice ( n = 6). (G) Protein expression levels of different markers across clusters. Data in E–G represent one representative experiment out of >3 independent experiments. (H) Representative density plots (gated on γδ T cells) and quantification of IFNγ + γδ T cells in tumors ( n = 22 control and 23 DTx mice). Fold change of percentage, numbers per milligram, and mean fluorescence intensity (MFI) over controls are represented. (I) Fold change of percentage of IL-17A + γδ T cells and numbers per milligram in tumors ( n = 22 Control and 23 DTx mice). (J) γδ T cell polarization measured by the ratio of percentages of IFNγ + versus IL-17A + γδ T cells (γδIFN/γδ17) ( n = 18 control and 19 DTx mice). Data in H–J are a pool of three different experiments. (K) Representative density plots (gated on IFNγ + γδ T cells) and quantification of proliferation of tumor IFNγ + γδ T cells, measured by Ki-67 ( n = 5 control 7 DTx mice) and BrdU ( n = 7 mice per group) staining. One representative out of two independent experiments. (L) Fold change of percentages of IFNγ + γδ T cells in the tumor dLNs spleen of control and DTx-treated mice ( n = 22 control and 23 DTx mice). (M) Fold change of percentages of Vγ subsets (within γδ T cells) in the tumors ( n = 22 control and 23 DTx mice). Data in L and M are a pool of three different experiments. (N) Fold change of percentages of granzyme B + cells within γδ T cells in tumors ( n = 10 control and 12 DTx mice), one representative out of three independent experiments. Data in H-N represented as means ± SEM and analyzed by unpaired t test for normal distributions or Mann–Whitney U test for non-normal distributions. (O) Quantification of tumor cell death of E0771 cells over a 24-h killing assay in the presence of γδ T cells, Treg cells, or both, measured by percentage of annexin V + cells ( n = 3–4 replicates). Data are represented as means ± SEM and analyzed by one-way ANOVA with Tukey’s post hoc test. One representative out of two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, and****P < 0.001.

Article Snippet: C57BL/6J Foxp3-DTR (B6.129 [Cg]-Foxp3tm3 [DTR/GFP] Ayr/J) (Foxp3-DTR [C57BL/6 background] [ ]) were obtained from The Jackson Laboratory and are backcrossed for at least eight generations to C57BL/6NTac mice, and NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(IL15)1Sz/SzJ (NSG-Tg[Hu-IL15] [NOD/ShiLtJ background]) were obtained from The Jackson Laboratory, and C57BL/6J FOXP3-hCD2/IL-17A-GFP (CD57BL/6 background) mice were bred in house from C57BL/6J FOXP3-hCD2 mice, kindly provided by Prof. Shohei Hori (University of Tokyo, Japan), and C57BL/6J IL-17A-GFP mice were obtained from Biocytogen.

Techniques: MANN-WHITNEY, Control, Flow Cytometry, Expressing, Fluorescence, Staining

IFNγ + γδ T cell expansion upon Treg cell depletion in MC38 colon cancer model and in tumor-free mice. (A) Schematic representation of the experimental approach. 2 × 10 6 of MC38 colon cancer cells were inoculated subcutaneously in the flank of Foxp3-DTR mice. DTx in PBS was administered intraperitoneally on days 6, 8, 10 (50 μg/kg), and 12 (25 μg/kg) after tumor inoculation. (B) Tumor growth of PBS- or DTx-treated mice ( n = 6 mice per group). Means ± SEM, repeated measures two-way ANOVA with Sidak’s multiple comparisons test. (C) Quantification of the frequency of IFNγ + γδ T cells and of proliferation of IFNγ + γδ T cells, measured by Ki-67 ( n = 6) staining, in tumors. (D) Schematic representation of the experimental approach. Foxp3-DTR mice were injected DTx in PBS on days 0, 2, 4 (1.5 μg), and 7 (0.75 μg). ( E ) Quantification of percentages of Treg cells and γδ T cells within CD45 + cells and quantification of IFNγ and IL-17A expression by γδ T cells in the spleen, inguinal LN, mammary fat, lung, and colonic lamina propria of DTx-treated or control mice. Data are represented as means ± SEM and analyzed by unpaired t test (for normal distributions) or Mann–Whitney U test (for non-normal distributions). Data are representative of two independent experiments. Data are represented as means ± SEM and analyzed by one-way ANOVA with Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, and ****P < 0.001.

Journal: The Journal of Experimental Medicine

Article Title: Regulatory T cells sabotage anti-tumor γδ T cells by creating IL-2–deficient environments

doi: 10.1084/jem.20252133

Figure Lengend Snippet: IFNγ + γδ T cell expansion upon Treg cell depletion in MC38 colon cancer model and in tumor-free mice. (A) Schematic representation of the experimental approach. 2 × 10 6 of MC38 colon cancer cells were inoculated subcutaneously in the flank of Foxp3-DTR mice. DTx in PBS was administered intraperitoneally on days 6, 8, 10 (50 μg/kg), and 12 (25 μg/kg) after tumor inoculation. (B) Tumor growth of PBS- or DTx-treated mice ( n = 6 mice per group). Means ± SEM, repeated measures two-way ANOVA with Sidak’s multiple comparisons test. (C) Quantification of the frequency of IFNγ + γδ T cells and of proliferation of IFNγ + γδ T cells, measured by Ki-67 ( n = 6) staining, in tumors. (D) Schematic representation of the experimental approach. Foxp3-DTR mice were injected DTx in PBS on days 0, 2, 4 (1.5 μg), and 7 (0.75 μg). ( E ) Quantification of percentages of Treg cells and γδ T cells within CD45 + cells and quantification of IFNγ and IL-17A expression by γδ T cells in the spleen, inguinal LN, mammary fat, lung, and colonic lamina propria of DTx-treated or control mice. Data are represented as means ± SEM and analyzed by unpaired t test (for normal distributions) or Mann–Whitney U test (for non-normal distributions). Data are representative of two independent experiments. Data are represented as means ± SEM and analyzed by one-way ANOVA with Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, and ****P < 0.001.

Techniques: Staining, Injection, Expressing, Control, MANN-WHITNEY

Treg cell depletion increases systemic IFNγ-producing αβ T cells and reveals the anti-tumor contribution of CD8 T cells. (A–C) Quantification of IFNγ + CD8 and CD4 (Th1) T cells as a fold change of percentage and numbers per milligram in (A) tumors or as a fold change of percentages in (B) dLNs and (C) spleen of DTx-treated over control mice. Data are represented as means ± SEM of a pool of three independent experiments and analyzed by unpaired t test for normal distributions or Mann–Whitney U test for non-normal distributions. (D) Schematic representation of the experimental approach. 1 × 10 6 of E0771 breast cancer cells were inoculated in the mammary fat pad of Foxp3-DTR mice. DTx in PBS was administered intraperitoneally on days 7, 9, 11 (1.5 μg), and 14 (0.75 μg) after tumor inoculation. On the same days, 100 μg of αCD8β mAb or isotype control was administered intraperitoneally. (E) Percentages of CD8 T cells (within CD45 + T cells) in tumors ( n = 6 isotype, 5 DTx + isotype, 6 αCD8β, and 5 DTx + αCD8β). Data are represented as means ± SEM and analyzed by one-way ANOVA with Tukey’s multiple comparisons test. (F) Tumor growth of mice treated with isotype ( n = 7), αCD8β ( n = 5), DTx + isotype ( n = 6), or DTx + αCD8β ( n = 5), analyzed by repeated measures two-way ANOVA with Sidak’s multiple comparisons test. (G) Percentages of γδ T cells (within CD45 + T cells) and IFNγ+ within γδ T cells ( n = 6 isotype, 5 DTx + isotype, 6 αCD8β, and 5 or DTx + αCD8β) in tumors. Data are representative of two independent experiments, are represented as means ± SEM, and analyzed by one-way ANOVA with Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.001.

Journal: The Journal of Experimental Medicine

Article Title: Regulatory T cells sabotage anti-tumor γδ T cells by creating IL-2–deficient environments

doi: 10.1084/jem.20252133

Figure Lengend Snippet: Treg cell depletion increases systemic IFNγ-producing αβ T cells and reveals the anti-tumor contribution of CD8 T cells. (A–C) Quantification of IFNγ + CD8 and CD4 (Th1) T cells as a fold change of percentage and numbers per milligram in (A) tumors or as a fold change of percentages in (B) dLNs and (C) spleen of DTx-treated over control mice. Data are represented as means ± SEM of a pool of three independent experiments and analyzed by unpaired t test for normal distributions or Mann–Whitney U test for non-normal distributions. (D) Schematic representation of the experimental approach. 1 × 10 6 of E0771 breast cancer cells were inoculated in the mammary fat pad of Foxp3-DTR mice. DTx in PBS was administered intraperitoneally on days 7, 9, 11 (1.5 μg), and 14 (0.75 μg) after tumor inoculation. On the same days, 100 μg of αCD8β mAb or isotype control was administered intraperitoneally. (E) Percentages of CD8 T cells (within CD45 + T cells) in tumors ( n = 6 isotype, 5 DTx + isotype, 6 αCD8β, and 5 DTx + αCD8β). Data are represented as means ± SEM and analyzed by one-way ANOVA with Tukey’s multiple comparisons test. (F) Tumor growth of mice treated with isotype ( n = 7), αCD8β ( n = 5), DTx + isotype ( n = 6), or DTx + αCD8β ( n = 5), analyzed by repeated measures two-way ANOVA with Sidak’s multiple comparisons test. (G) Percentages of γδ T cells (within CD45 + T cells) and IFNγ+ within γδ T cells ( n = 6 isotype, 5 DTx + isotype, 6 αCD8β, and 5 or DTx + αCD8β) in tumors. Data are representative of two independent experiments, are represented as means ± SEM, and analyzed by one-way ANOVA with Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.001.

Techniques: Control, MANN-WHITNEY

IFNγ-biased Vγ1 + γδ T cells are anti-tumor effectors of Treg depletion therapy. ( A ) Schematic representation of the experimental approach. 1 × 10 6 of E0771 breast cancer cells were inoculated in the mammary fat pad of Foxp3-DTR mice. DTx in PBS was administered intraperitoneally on days 7, 9, 11 (1.5 μg), and 14 (0.75 μg) after tumor inoculation. On the same days, 100 μg of αVγ1 mAb or isotype control was administered intraperitoneally. (B) Tumor growth of mice treated with PBS + isotype ( n = 10), DTx + isotype ( n = 9), PBS + αVγ1 ( n = 9), or DTx + αVγ1 ( n = 7). Pool of two independent experiments, repeated measures two-way ANOVA with Sidak’s multiple comparisons test. (C) Percentages of Treg cells in tumors at day 15 after tumor inoculation. (D) Percentages of γδ T cells (within CD45 + T cells) and Vγ1 + and Vγ4 + cells within γδ T cells ( n = 10 PBS + isotype, 9 DTx + isotype, 9 PBS + αVγ1, and 7 DTx + αVγ1). Data in C and D, represented as means ± SEM, are a pool of two independent experiments and analyzed by one-way ANOVA with Tukey’s multiple comparisons test. (E) Percentage of IFNγ + cells within γδ T cells and representative density plots. (F) Percentage of IFNγ-producing CD4 and CD8 αβ T cells. Data in E and F, represented as means ± SEM ( n = 5 PBS + isotype, 4 DTx + isotype, 6 PBS + αVγ1, and 3 DTx + αVγ1), are representative of two independent experiments and were analyzed by one-way ANOVA with Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.001.

Journal: The Journal of Experimental Medicine

Article Title: Regulatory T cells sabotage anti-tumor γδ T cells by creating IL-2–deficient environments

doi: 10.1084/jem.20252133

Figure Lengend Snippet: IFNγ-biased Vγ1 + γδ T cells are anti-tumor effectors of Treg depletion therapy. ( A ) Schematic representation of the experimental approach. 1 × 10 6 of E0771 breast cancer cells were inoculated in the mammary fat pad of Foxp3-DTR mice. DTx in PBS was administered intraperitoneally on days 7, 9, 11 (1.5 μg), and 14 (0.75 μg) after tumor inoculation. On the same days, 100 μg of αVγ1 mAb or isotype control was administered intraperitoneally. (B) Tumor growth of mice treated with PBS + isotype ( n = 10), DTx + isotype ( n = 9), PBS + αVγ1 ( n = 9), or DTx + αVγ1 ( n = 7). Pool of two independent experiments, repeated measures two-way ANOVA with Sidak’s multiple comparisons test. (C) Percentages of Treg cells in tumors at day 15 after tumor inoculation. (D) Percentages of γδ T cells (within CD45 + T cells) and Vγ1 + and Vγ4 + cells within γδ T cells ( n = 10 PBS + isotype, 9 DTx + isotype, 9 PBS + αVγ1, and 7 DTx + αVγ1). Data in C and D, represented as means ± SEM, are a pool of two independent experiments and analyzed by one-way ANOVA with Tukey’s multiple comparisons test. (E) Percentage of IFNγ + cells within γδ T cells and representative density plots. (F) Percentage of IFNγ-producing CD4 and CD8 αβ T cells. Data in E and F, represented as means ± SEM ( n = 5 PBS + isotype, 4 DTx + isotype, 6 PBS + αVγ1, and 3 DTx + αVγ1), are representative of two independent experiments and were analyzed by one-way ANOVA with Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.001.

Techniques: Control

Inhibition of IL-10, IL-35, and adenosine pathways does not impact Treg-mediated suppression of IFNγ + γδ T cells. (A) Quantification of proliferation index of IFNγ + γδ T cells in the presence or absence of Treg cells and in the presence of αIL-10– or αIL-35–neutralizing antibody or the CD39 inhibitor ARL67156 (fold change over γδ T cells only is represented). Data are representative of two independent experiments. (B) Schematic representation of the experimental approach. 1 × 106 of E0771 breast cancer cells were inoculated in the mammary fat pad of Foxp3-DTR mice (without any DTx administration). In addition, 200 μg of αIL-10–neutralizing antibody was administered intraperitoneally on days −1, 0, 1, and 3 relative to tumor inoculation, followed by intratumoral injections on days 7, 10, and 13. (C) Tumor growth of αIL-10–treated or control mice ( n = 7 mice per group). Data are analyzed by repeated measures two-way ANOVA with Sidak’s multiple comparisons test without reaching significant differences between the two groups. (D) Percentages of γδ T cells within CD3 + T cells ( n = 7 mice per group) and IFNγ + cells within γδ T cells ( n = 6 mice per group). Data are represented as means ± SEM and analyzed by unpaired t test. **P < 0.01 and ****P < 0.001.

Journal: The Journal of Experimental Medicine

Article Title: Regulatory T cells sabotage anti-tumor γδ T cells by creating IL-2–deficient environments

doi: 10.1084/jem.20252133

Figure Lengend Snippet: Inhibition of IL-10, IL-35, and adenosine pathways does not impact Treg-mediated suppression of IFNγ + γδ T cells. (A) Quantification of proliferation index of IFNγ + γδ T cells in the presence or absence of Treg cells and in the presence of αIL-10– or αIL-35–neutralizing antibody or the CD39 inhibitor ARL67156 (fold change over γδ T cells only is represented). Data are representative of two independent experiments. (B) Schematic representation of the experimental approach. 1 × 106 of E0771 breast cancer cells were inoculated in the mammary fat pad of Foxp3-DTR mice (without any DTx administration). In addition, 200 μg of αIL-10–neutralizing antibody was administered intraperitoneally on days −1, 0, 1, and 3 relative to tumor inoculation, followed by intratumoral injections on days 7, 10, and 13. (C) Tumor growth of αIL-10–treated or control mice ( n = 7 mice per group). Data are analyzed by repeated measures two-way ANOVA with Sidak’s multiple comparisons test without reaching significant differences between the two groups. (D) Percentages of γδ T cells within CD3 + T cells ( n = 7 mice per group) and IFNγ + cells within γδ T cells ( n = 6 mice per group). Data are represented as means ± SEM and analyzed by unpaired t test. **P < 0.01 and ****P < 0.001.

Techniques: Inhibition, Control

IL-2 neutralization in the absence of Treg cells limits anti-tumor γδ T cell responses and impairs tumor control. (A) Schematic representation of the experimental approach. 1 × 10 6 of E0771 breast cancer cells were inoculated in the mammary fat pad of Foxp3-DTR mice. DTx in PBS was administered intraperitoneally on days 7, 9, 11 (1.5 μg), and 14 (0.75 μg) after tumor inoculation. Between days 7 and 14 a combo of two αIL-2 antibodies (100 μg of S46B6-1 and 100 μg of JES6-1A12) or isotype controls was administered intraperitoneally daily to neutralize IL-2. (B) Tumor growth of PBS + isotype- (control), DTx + isotype-, PBS + αIL-2–, or DTx + αIL-2–treated mice ( n = 5 mice per group). Data are representative of two independent experiments with similar trends and were analyzed by repeated measures two-way ANOVA with Sidak’s multiple comparisons test. (C) Percentages of Treg cells in tumors at day 15 after tumor inoculation. (D and E) (D) Percentages of γδ T cells within CD45 + T cells and (E) CD25 expression within γδ T cells. (F) Percentage of IFNγ + cells and granzyme B + cells within γδ T cells and representative density plots. Data in C–F correspond to a pool of two independent experiments with similar trends ( n = 10 PBS + isotype, 10 DTx + isotype, 5 PBS + αIL-2, or 9 DTx + αIL-2, represented as means ± SEM and analyzed by one-way ANOVA with Tukey’s multiple comparisons test). (G) Quantification of proliferation of IFNγ + γδ T cells by Ki-67 expression ( n = 5 mice per group). One representative out of two independent experiments, analyzed by one-way ANOVA with Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.001.

Journal: The Journal of Experimental Medicine

Article Title: Regulatory T cells sabotage anti-tumor γδ T cells by creating IL-2–deficient environments

doi: 10.1084/jem.20252133

Figure Lengend Snippet: IL-2 neutralization in the absence of Treg cells limits anti-tumor γδ T cell responses and impairs tumor control. (A) Schematic representation of the experimental approach. 1 × 10 6 of E0771 breast cancer cells were inoculated in the mammary fat pad of Foxp3-DTR mice. DTx in PBS was administered intraperitoneally on days 7, 9, 11 (1.5 μg), and 14 (0.75 μg) after tumor inoculation. Between days 7 and 14 a combo of two αIL-2 antibodies (100 μg of S46B6-1 and 100 μg of JES6-1A12) or isotype controls was administered intraperitoneally daily to neutralize IL-2. (B) Tumor growth of PBS + isotype- (control), DTx + isotype-, PBS + αIL-2–, or DTx + αIL-2–treated mice ( n = 5 mice per group). Data are representative of two independent experiments with similar trends and were analyzed by repeated measures two-way ANOVA with Sidak’s multiple comparisons test. (C) Percentages of Treg cells in tumors at day 15 after tumor inoculation. (D and E) (D) Percentages of γδ T cells within CD45 + T cells and (E) CD25 expression within γδ T cells. (F) Percentage of IFNγ + cells and granzyme B + cells within γδ T cells and representative density plots. Data in C–F correspond to a pool of two independent experiments with similar trends ( n = 10 PBS + isotype, 10 DTx + isotype, 5 PBS + αIL-2, or 9 DTx + αIL-2, represented as means ± SEM and analyzed by one-way ANOVA with Tukey’s multiple comparisons test). (G) Quantification of proliferation of IFNγ + γδ T cells by Ki-67 expression ( n = 5 mice per group). One representative out of two independent experiments, analyzed by one-way ANOVA with Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.001.

Techniques: Neutralization, Control, Expressing

IL-2Rβ γ c agonism promotes anti-tumor murine γδ T cell responses and tumor control. (A) Schematic representation of the experimental approach. 1 × 10 6 of E0771 breast cancer cells were inoculated in the mammary fat pad of Foxp3-DTR mice (without any DTx administration), and 10 μg of Neo2/15 was administered intraperitoneally daily between days 7 and 14 in the indicated group. (B) Tumor growth of Neo2/15-treated or control mice ( n = 9 mice per group). Data were analyzed by repeated measures two-way ANOVA with Sidak’s multiple comparisons test. (C) Percentages of Treg cells in tumors at day 15 after tumor inoculation ( n = 9 mice per group). (D and E) (D) Percentages of γδ T cells within CD45 + T cells and (E) CD25 expression within γδ T cells ( n = 9 mice per group). Data in B–E are represented as means ± SEM of a pool of two independent experiments and analyzed by unpaired t test. (F) Percentage of IFNγ + cells and granzyme B + cells within γδ T cells and representative density plots ( n = 5 control mice and 4 Neo2/15-treated mice). Data are represented as means ± SEM of one representative out of two independent experiments and analyzed by unpaired t test. (G) Schematic representation of the experimental approach to deplete Vγ1 + γδ T cells together with Neo2/15 administration. Briefly, 1 × 106 of E0771 breast cancer cells were inoculated in the mammary fat pad of Foxp3-DTR mice. 10 μg of Neo2/15 in PBS was daily administered intraperitoneally. In addition, 100 μg αVγ1 mAb or isotype control was intraperitoneally administered on days 7, 9, 11, and 14 after tumor inoculation. (H) Tumor growth of mice treated with isotype ( n = 5), Neo2/15 ( n = 5) or Neo2/15 + αVγ1 ( n = 5), analyzed by repeated measures two-way ANOVA with Sidak’s multiple comparisons test and were representative of two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.001.

Journal: The Journal of Experimental Medicine

Article Title: Regulatory T cells sabotage anti-tumor γδ T cells by creating IL-2–deficient environments

doi: 10.1084/jem.20252133

Figure Lengend Snippet: IL-2Rβ γ c agonism promotes anti-tumor murine γδ T cell responses and tumor control. (A) Schematic representation of the experimental approach. 1 × 10 6 of E0771 breast cancer cells were inoculated in the mammary fat pad of Foxp3-DTR mice (without any DTx administration), and 10 μg of Neo2/15 was administered intraperitoneally daily between days 7 and 14 in the indicated group. (B) Tumor growth of Neo2/15-treated or control mice ( n = 9 mice per group). Data were analyzed by repeated measures two-way ANOVA with Sidak’s multiple comparisons test. (C) Percentages of Treg cells in tumors at day 15 after tumor inoculation ( n = 9 mice per group). (D and E) (D) Percentages of γδ T cells within CD45 + T cells and (E) CD25 expression within γδ T cells ( n = 9 mice per group). Data in B–E are represented as means ± SEM of a pool of two independent experiments and analyzed by unpaired t test. (F) Percentage of IFNγ + cells and granzyme B + cells within γδ T cells and representative density plots ( n = 5 control mice and 4 Neo2/15-treated mice). Data are represented as means ± SEM of one representative out of two independent experiments and analyzed by unpaired t test. (G) Schematic representation of the experimental approach to deplete Vγ1 + γδ T cells together with Neo2/15 administration. Briefly, 1 × 106 of E0771 breast cancer cells were inoculated in the mammary fat pad of Foxp3-DTR mice. 10 μg of Neo2/15 in PBS was daily administered intraperitoneally. In addition, 100 μg αVγ1 mAb or isotype control was intraperitoneally administered on days 7, 9, 11, and 14 after tumor inoculation. (H) Tumor growth of mice treated with isotype ( n = 5), Neo2/15 ( n = 5) or Neo2/15 + αVγ1 ( n = 5), analyzed by repeated measures two-way ANOVA with Sidak’s multiple comparisons test and were representative of two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.001.

Techniques: Control, Expressing

Foxp3 EGFP-Cre-ERT2 control mice and Foxp3 EGFP-Cre-ERT2 x Ccr4 fl/fl mice were sensitized with 10 µg i.n. HDM followed by daily challenges of 10 µg i.n. HDM on days 7–11, 1 mg daily doses of tamoxifen via oral gavage on days 4-8, then injected with anti-CD45 antibody i.v. 3 minutes prior to tissue harvest on day 14. A. Acute intranasal HDM and tamoxifen treatment protocol. B. Representative flow cytometry of lung intraparenchymal (anti-CD45 i.v. antibody negative) CD4 + T cells showing Foxp3 and CCR4 expression from indicated groups. C. Percent lung CCR4 + Foxp3 + Tregs among Foxp3 + Tregs from indicated groups. D. Percentage of Foxp3 + Tregs among lung CD4 + T cells and number of total lung Tregs from indicated groups. E. Number of total lung DC subsets from indicated groups. F. Number of PD-L2 + CCR7 + lung cDC2s. G. Number of lung eosinophils H. Percentage of Foxp3 - ST2 + T cells (Th2 cells) among lung CD4 + T cells and number of total lung Th2 cells . I. Representative PAS-stained lung sections. J. Mucus scores. Foxp3 EGFP-Cre-ERT2 control mice and Foxp3 EGFP-Cre-ERT2 x Ccr4 fl/fl mice were administered 10 µg i.n HDM 3 times per week for 6 weeks alongside 1 mg daily doses of tamoxifen via oral gavage on days 4-8, 18-22 and 32-36 of HDM treatment then injected with anti-CD45 antibody i.v. 3 minutes prior to tissue harvest on day 42. K. Chronic intranasal HDM and tamoxifen treatment protocol. L. Representative flow cytometry of lung CD4 + T cells showing Foxp3 and CCR4 expression from indicated groups. M. Percentage of lung CCR4 + Foxp3 + Tregs. N. Number of lung Tregs. O. Number of lung DC subsets. P. Number of PD-L2 + CCR7 + lung cDC2s. Q. Number of lung eosinophils R. Number of lung Th2 cells. Data are from three independent experiments with 11-18 mice pooled (A-J) or data are from two independent experiments with 12 mice pooled (K-R). For statistical analysis, a two-tailed t test was performed for parametric data, and a two-tailed Mann-Whitney U test was performed for nonparametric data. One-way ANOVA analysis with Holm-Sidak’s testing for multiple comparisons. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; ns, not significant.

Journal: bioRxiv

Article Title: Type 2 conventional dendritic cells and regulatory T cells form a barrier tissue circuit to control allergic inflammation

doi: 10.64898/2026.05.04.722795

Figure Lengend Snippet: Foxp3 EGFP-Cre-ERT2 control mice and Foxp3 EGFP-Cre-ERT2 x Ccr4 fl/fl mice were sensitized with 10 µg i.n. HDM followed by daily challenges of 10 µg i.n. HDM on days 7–11, 1 mg daily doses of tamoxifen via oral gavage on days 4-8, then injected with anti-CD45 antibody i.v. 3 minutes prior to tissue harvest on day 14. A. Acute intranasal HDM and tamoxifen treatment protocol. B. Representative flow cytometry of lung intraparenchymal (anti-CD45 i.v. antibody negative) CD4 + T cells showing Foxp3 and CCR4 expression from indicated groups. C. Percent lung CCR4 + Foxp3 + Tregs among Foxp3 + Tregs from indicated groups. D. Percentage of Foxp3 + Tregs among lung CD4 + T cells and number of total lung Tregs from indicated groups. E. Number of total lung DC subsets from indicated groups. F. Number of PD-L2 + CCR7 + lung cDC2s. G. Number of lung eosinophils H. Percentage of Foxp3 - ST2 + T cells (Th2 cells) among lung CD4 + T cells and number of total lung Th2 cells . I. Representative PAS-stained lung sections. J. Mucus scores. Foxp3 EGFP-Cre-ERT2 control mice and Foxp3 EGFP-Cre-ERT2 x Ccr4 fl/fl mice were administered 10 µg i.n HDM 3 times per week for 6 weeks alongside 1 mg daily doses of tamoxifen via oral gavage on days 4-8, 18-22 and 32-36 of HDM treatment then injected with anti-CD45 antibody i.v. 3 minutes prior to tissue harvest on day 42. K. Chronic intranasal HDM and tamoxifen treatment protocol. L. Representative flow cytometry of lung CD4 + T cells showing Foxp3 and CCR4 expression from indicated groups. M. Percentage of lung CCR4 + Foxp3 + Tregs. N. Number of lung Tregs. O. Number of lung DC subsets. P. Number of PD-L2 + CCR7 + lung cDC2s. Q. Number of lung eosinophils R. Number of lung Th2 cells. Data are from three independent experiments with 11-18 mice pooled (A-J) or data are from two independent experiments with 12 mice pooled (K-R). For statistical analysis, a two-tailed t test was performed for parametric data, and a two-tailed Mann-Whitney U test was performed for nonparametric data. One-way ANOVA analysis with Holm-Sidak’s testing for multiple comparisons. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; ns, not significant.

Article Snippet: Ccr4 floxed mice were crossed to Foxp3 EGFP-Cre-ERT2 mice ( Foxp3 EGFP-Cre-ERT2 ; stock no. 016961) purchased from the Jackson Laboratory to generate Foxp3 EGFP-Cre-ERT2 x Ccr4 floxed mice.

Techniques: Control, Injection, Flow Cytometry, Expressing, Staining, Two Tailed Test, MANN-WHITNEY

Journal: bioRxiv

Article Title: Type 2 conventional dendritic cells and regulatory T cells form a barrier tissue circuit to control allergic inflammation

doi: 10.64898/2026.05.04.722795

Figure Lengend Snippet: Foxp3 EGFP-Cre-ERT2 control mice and Foxp3 EGFP-Cre-ERT2 x Ccr4 fl/fl mice were sensitized with 10 µg i.n. HDM followed by daily challenges of 10 µg i.n. HDM on days 7–11, 1 mg daily doses of tamoxifen via oral gavage on days 4-8, then injected with anti-CD45 antibody i.v. 3 minutes prior to tissue harvest on day 14. A . % Ki67 + and gMFI for TIGIT, GITR, ICOS, and ST2 in lung Tregs from indicated groups. B . Percentage PD-L2 + CCR7 + cDC2s of total lung cDC2s. C . Total number of lung neutrophils. D . Percentage of lung ILC2s of lineage - cells and total number of lung ILC2s. E . Percentage and number of lung Th1 cells. F . Percentage and number of lung Th17 cells. G . Percent LN CCR4 + Foxp3 + Tregs. H . Percentage LN Tregs. I . Number of LN Tregs. J . Percentage and number of LN Th2 cells. K . Number of total LN DC subsets. L . Percentage and total number of PD-L2 + CCR7 + of LN cDC2s. M . Serum IgE levels. N-Q . Foxp3 EGFP-Cre-ERT2 control mice and Foxp3 EGFP-Cre-ERT2 x Ccr4 fl/fl mice were administered 10 µg i.n HDM 3 times per week for 6 weeks, 1 mg daily doses of tamoxifen via oral gavage on days 4-8, 18-22 and 32-36 of HDM treatment, then injected with anti-CD45 antibody i.v. 3 minutes prior to tissue harvest on day 42. N . Percentage of lung Tregs of total CD4 + T cells from indicated groups. O . Percentage PD-L2 + CCR7 + cDC2s of total lung cDC2s. P . Representative PAS-stained lung sections. Q . Mucus scores. Data are from three independent experiments with 11-18 mice pooled or data are representative of one experiment with n L=L5 mice per group from three independent experiments. For statistical analysis, a two-tailed t test was performed for parametric data, and a two-tailed Mann-Whitney U test was performed for nonparametric data. One-way ANOVA analysis with Holm-Sidak’s testing for multiple comparisons. *, p<0.05; ****, p<0.0001, ns, not significant.

Techniques: Control, Injection, Staining, Two Tailed Test, MANN-WHITNEY

CCR4 promotes the efficiency of Treg trafficking to suppress the expansion of CCR7+ cDC2-CD4+ T cell clusters during allergic inflammation. Foxp3 EGFP-Cre-ERT2 control mice and Foxp3 EGFP-Cre-ERT2 x Ccr4 fl/fl mice were sensitized with 10 µg i.n. HDM followed by daily challenges of 10 µg i.n. HDM on days 7–11, 1 mg daily doses of tamoxifen via oral gavage on days 4-8, then injected with anti-CD45 antibody i.v. 3 minutes prior to tissue harvest on day 14. A. Representative imaging of lungs from indicated groups with staining for CD4 (Cyan), Foxp3 (Red), and FSCN1 (Yellow). B. Higher magnification of images shown in (A). C-D. Quantification of nearest distance (µm) between FSCN1 + DCs and Foxp3 + Tregs (C) and FSCN1 + DCs and CD4 + T cells (D). E-G . Mixed bone marrow chimeras were generated with Foxp3 EGFP-Cre-ERT2 Thy1.1 + Thy1.2 + control and Foxp3 EGFP-Cre-ERT2 x Ccr4 fl/fl (Thy1.2) bone marrow cells. Ctrl: Ccr4 cKO mixed bone marrow chimeras were treated with HDM (days 0, 7-11) and tamoxifen via oral gavage (days 4-8) then injected with anti-CD45 antibody i.v. 3 minutes prior to tissue harvest on day 14. E. Representative flow cytometry of lung CD4 + T cells showing Foxp3 + and Thy1.1 + Thy1.2 + (Ctrl) and Thy1.2 + ( Ccr4 cKO) Tregs. F. Ratio of Ctrl: Ccr4 cKO Tregs in the lymph nodes and lungs. G. Ratio of Ctrl: Ccr4 cKO Th2 cells in the lymph nodes and lungs. H. Volcano plot showing differential gene expression analysis of bulk transcriptomes between sorted lung Tregs from Foxp3 EGFP-Cre-ERT2 control mice and Foxp3 EGFP-Cre-ERT2 x Ccr4 fl/fl mice treated with HDM and tamoxifen. I . Asb2 relative RNA expression in iTregs cultured with or without rIL-4 for 2 days. J . Mixed bone marrow chimeras were generated with C57BL/6 control (Ctrl) and Il4r α-deficient bone marrow cells. Ctrl: Il4ra -deficient mixed bone marrow chimeras were treated with HDM (days 0, 7-11) then injected with anti-CD45 antibody i.v. 3 minutes prior to tissue harvest on day 14. Ctrl: Il4ra KO ratio of lung T cell subsets. Images are representative of one of two independent experiments (A-B), data were pooled form two independent experiments (C-D), or data are representative of one experiment with n L=L10 mice per group from two independent experiments (E-G), or data were pooled form two independent experiments with n = 6 mice per group (H), or data were pooled from nine independent experiments (I), or data were pooled from two independent experiments with n = 10 mice (J). For statistical analysis, a two-tailed t test was performed for parametric data, and a two-tailed Mann-Whitney U test was performed for nonparametric data. **, p<0.001; ****, p<0.0001; ns, not significant.

Journal: bioRxiv

Article Title: Type 2 conventional dendritic cells and regulatory T cells form a barrier tissue circuit to control allergic inflammation

doi: 10.64898/2026.05.04.722795

Figure Lengend Snippet: CCR4 promotes the efficiency of Treg trafficking to suppress the expansion of CCR7+ cDC2-CD4+ T cell clusters during allergic inflammation. Foxp3 EGFP-Cre-ERT2 control mice and Foxp3 EGFP-Cre-ERT2 x Ccr4 fl/fl mice were sensitized with 10 µg i.n. HDM followed by daily challenges of 10 µg i.n. HDM on days 7–11, 1 mg daily doses of tamoxifen via oral gavage on days 4-8, then injected with anti-CD45 antibody i.v. 3 minutes prior to tissue harvest on day 14. A. Representative imaging of lungs from indicated groups with staining for CD4 (Cyan), Foxp3 (Red), and FSCN1 (Yellow). B. Higher magnification of images shown in (A). C-D. Quantification of nearest distance (µm) between FSCN1 + DCs and Foxp3 + Tregs (C) and FSCN1 + DCs and CD4 + T cells (D). E-G . Mixed bone marrow chimeras were generated with Foxp3 EGFP-Cre-ERT2 Thy1.1 + Thy1.2 + control and Foxp3 EGFP-Cre-ERT2 x Ccr4 fl/fl (Thy1.2) bone marrow cells. Ctrl: Ccr4 cKO mixed bone marrow chimeras were treated with HDM (days 0, 7-11) and tamoxifen via oral gavage (days 4-8) then injected with anti-CD45 antibody i.v. 3 minutes prior to tissue harvest on day 14. E. Representative flow cytometry of lung CD4 + T cells showing Foxp3 + and Thy1.1 + Thy1.2 + (Ctrl) and Thy1.2 + ( Ccr4 cKO) Tregs. F. Ratio of Ctrl: Ccr4 cKO Tregs in the lymph nodes and lungs. G. Ratio of Ctrl: Ccr4 cKO Th2 cells in the lymph nodes and lungs. H. Volcano plot showing differential gene expression analysis of bulk transcriptomes between sorted lung Tregs from Foxp3 EGFP-Cre-ERT2 control mice and Foxp3 EGFP-Cre-ERT2 x Ccr4 fl/fl mice treated with HDM and tamoxifen. I . Asb2 relative RNA expression in iTregs cultured with or without rIL-4 for 2 days. J . Mixed bone marrow chimeras were generated with C57BL/6 control (Ctrl) and Il4r α-deficient bone marrow cells. Ctrl: Il4ra -deficient mixed bone marrow chimeras were treated with HDM (days 0, 7-11) then injected with anti-CD45 antibody i.v. 3 minutes prior to tissue harvest on day 14. Ctrl: Il4ra KO ratio of lung T cell subsets. Images are representative of one of two independent experiments (A-B), data were pooled form two independent experiments (C-D), or data are representative of one experiment with n L=L10 mice per group from two independent experiments (E-G), or data were pooled form two independent experiments with n = 6 mice per group (H), or data were pooled from nine independent experiments (I), or data were pooled from two independent experiments with n = 10 mice (J). For statistical analysis, a two-tailed t test was performed for parametric data, and a two-tailed Mann-Whitney U test was performed for nonparametric data. **, p<0.001; ****, p<0.0001; ns, not significant.

Techniques: Control, Injection, Imaging, Staining, Generated, Flow Cytometry, Gene Expression, RNA Expression, Cell Culture, Two Tailed Test, MANN-WHITNEY

Journal: bioRxiv

Article Title: Type 2 conventional dendritic cells and regulatory T cells form a barrier tissue circuit to control allergic inflammation

doi: 10.64898/2026.05.04.722795

Techniques: Control, Injection, Expressing, Two Tailed Test

Review

Structured Review

Images

Similar Products

Image Search Results